501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
The newly emerging variants of SARS-CoV-2 from South Africa (B.1.351/501Y.V2) and Brazil (P.1/501Y.V3) have led to a higher infection rate and reinfection of COVID-19 patients. We found that the mutations K417N, E484K, and N501Y within the receptor-binding domains (RBDs) of the virus could confer ~2...
Main Authors: | Haolin Liu, Pengcheng Wei, Qianqian Zhang, Zhongzhou Chen, Katja Aviszus, Walter Downing, Shelley Peterson, Lyndon Reynoso, Gregory P. Downey, Stephen K. Frankel, John Kappler, Philippa Marrack, Gongyi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2021.1919285 |
Similar Items
-
Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications
by: Jasdeep Singh, et al.
Published: (2021-03-01) -
Possible Role of Accessory Proteins in the Viral Replication for the 20I/501Y.V1 (B.1.1.7) SARS CoV-2 Variant
by: Dimpal A. Nyayanit, et al.
Published: (2021-12-01) -
Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection
by: Fang-Ju Cheng, et al.
Published: (2021-08-01) -
Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2
by: Shi Zhao, et al.
Published: (2021-04-01) -
Evolution of SARS-CoV-2 Key Mutations in Vienna Detected by Large Scale Screening Program
by: Jakob Thannesberger, et al.
Published: (2021-10-01)